臨床上，癌症治療除了以抗癌藥物直接造成癌組織的死亡之外，常同時搭配血管新生抑制劑，阻斷患部的血管新生，避免殘餘的癌組織持續獲取營養繼續成長以及可能發生的轉移。傳統上，PLGA藥物載體大多應用於長效釋放，其釋放機制主要為PLGA微粒水解後的藥物釋放，其於癌症的治療上，常被質疑可能造成患部藥物濃度不足的疑慮。本研究以治療癌症為模擬應用目標，利用雙乳化方法製備出表面具有奈米級孔洞的PLGA微球，其上披覆能與細胞快速融合的微脂體，提出一可兩階段控制釋放系統: 微脂體進行細胞融合快速於胞內釋放第一階段抗癌藥物，PLGA多孔微球則於其後進行第二階段胞外釋放藥物。
　　實驗分為三大部分，第一部分為利用雙乳化方法製備出PLGA多孔微粒，探討不同濃度PBS對於PLGA微粒表面孔洞形態的影響，找出最適化的參數。第二部分則是檢驗不同孔洞大小的PLGA微粒以及表面披覆有微脂體的微粒，放置於模擬體內環境的PBS緩衝液下，探討包覆於PLGA多孔微粒其中的Hoechst釋放情形；同時也利用掃描式電子顯微鏡觀察披覆微脂體後微粒表面形態的改變。第三部份是以人類纖維肉瘤細胞(HT1080)做為細胞測試的模型，將披覆微脂體的PLGA微粒與細胞共培養後，利用螢光顯微鏡觀察細胞膜與細胞核是否會分別呈現出綠色螢光及紅色螢光以驗證微脂體與細胞膜融合並且釋放藥物Doxorubicin，並觀察帶有螢光染劑(DiD)的PLGA多孔微粒是否可避免被細胞吞食停留在細胞外釋放第二種藥物。由以上三部分的實驗可驗證我們所製備的微脂體能夠迅速與細胞膜融合於胞內釋放第一種藥物，而PLGA多孔微粒則可以避免被細胞吞噬在胞外釋放第二種藥物。藉由此二階段藥物釋放劑型，可使抗癌藥物Doxorubicin迅速於胞內釋放毒殺癌細胞，再於胞外緩慢釋放作用期較長之抑制血管新生藥物，加強前者的療效，而改善、提高癌症之治療效果。

[1] 張靜宜. 聚癸二酸酐－聚乳酸三團聯共聚物之合成、鑑定及其應用於藥物釋放之研究: 國立清華大學; 2005.
[2] Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56:581-7.
[3] Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery. J Control Release. 2005;104:51-66.
[4] 黃培傑. 具酸鹼敏感性可快速釋放藥物之載體系統: 國立清華大學; 2010.
[5] Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chemical reviews. 1999;99:3181-98.
[6] Khang G, Jeon JH, Cho JC, Lee HB. Fabrication of tubular porous PLGA scaffold by emulsion freeze-drying method. Polym-Korea. 1999;23:471-7.
[7] Jalil R, Nixon JR. Biodegradable Poly(Lactic Acid) and Poly(Lactide-Co-Glycolide) Microcapsules - Problems Associated with Preparative Techniques and Release Properties. J Microencapsul. 1990;7:297-325.
[8] Heller J. Controlled Drug Release from Poly(Ortho Esters). Annals of the New York Academy of Sciences. 1985;446:51-66.
[9] Heller J. Controlled Release of Biologically-Active Compounds from Bioerodible Polymers. Biomaterials. 1980;1:51-7.
[10] Dixit V, Elcin M, Arthur M, Gitnick G. Functional characteristics of primary rat hepatocytes in monolayers and on three-dimensional PLGA scaffold. Gastroenterology. 1999;116:A1204-A1204.
[11] Oh JH. In vivo comparison of corneal substitutes using PLGA scaffold, Type I collagen film, Type I collagen film combined with amniotic membrane and lyophilized homologous cornea. Invest Ophth Vis Sci. 2002;43:U1190-U1190.
[12] Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomat Sci-Polym E. 2006;17:247-89.
[13] Kitchell JP, Wise DL. Poly(Lactic Glycolic Acid) Biodegradable Drug Polymer Matrix Systems. Method Enzymol. 1985;112:436-48.
[14] Cohen S, Alonso MJ, Langer R. Novel approaches to controlled-release antigen delivery. International journal of technology assessment in health care. 1994;10:121-30.
[15] Wang Z. Effects of the Process Parameters on the Initial Burst Release of Poly(lactide-co-glycolide) Microspheres Containing Bovine Serum Albumin by the Double-Emulsion Solvent Evaporation/Extraction Method. J Appl Polym Sci. 2010;115:2599-608.
[16] Jeffery H, Davis SS, Ohagan DT. The Preparation and Characterization of Poly(Lactide-Co-Glycolide) Microparticles .1. Oil-in-Water Emulsion Solvent Evaporation. Int J Pharm. 1991;77:169-75.
[17] Li Z, Li XW, Zheng LQ, Lin XH, Geng F, Yu L. Bovine Serum Albumin Loaded Solid Lipid Nanoparticles Prepared by Double Emulsion Method. Chem Res Chinese U. 2010;26:136-41.
[18] Lee J, Oh YJ, Lee SK, Lee KY. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. J Control Release. 2010;146:61-7.
[19] Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW. Protein-Associated Deoxyribonucleic-Acid Strand Breaks in L1210 Cells Treated with the Deoxyribonucleic-Acid Intercalating Agents 4'-(9-Acridinylamino)Methanesulfon-M-Anisidide and Adriamycin. Biochemistry-Us. 1981;20:6553-63.
[20] Nelson EM, Tewey KM, Liu LF. Mechanism of Antitumor Drug-Action - Poisoning of Mammalian DNA Topoisomerase-Ii on DNA by 4'-(9-Acridinylamino)-Methanesulfon-Meta-Anisidide. P Natl Acad Sci-Biol. 1984;81:1361-5.
[21] 邱崙捷. 磁性奈米顆粒結合抗癌藥Doxorubicin之體內及體外抗腫瘤實驗: 國立成功大學; 2004.
[22] 黃堯焜. 溶媒添加對擠壓成形法製備微脂體包覆藥物之影響與評估: 元智大學; 2008.
[23] 陳麗舟. 微脂粒包覆染髮劑之製備與功能性評估: 樹德科技大學; 2008.
[24] 羅浚育. 界面活性劑與微脂粒的作用: 國立中央大學; 1999.
[25] Rongen HA, Bult A, van Bennekom WP. Liposomes and immunoassays. Journal of immunological methods. 1997;204:105-33.
[26] 吳銘斌、吳梨華、曾慶誠、周振陽. 抗血管新生療法在人類腫瘤的應用（一）. 秀傳醫學雜誌Show-Chwan Med J2004.
[27] Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, et al. Tumor Angiogenesis - Therapeutic Implications. New Engl J Med. 1971;285:1182-6.
[28] Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996;32A:2534-9.
[29] Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375-9.
[30] 吳銘斌、吳梨華、曾慶誠、周振陽. 抗血管新生療法在人類腫瘤的應用（二）. 秀傳醫學雜誌Show-Chwan Med J2004.
[31] Li CY, Shan SQ, Cao YT, Dewhirst MW. Role of incipient angiogenesis in cancer metastasis. Cancer Metast Rev. 2000;19:7-11.
[32] Lennernas B, Albertsson P, Lennernas H, Norrby K. Chemotherapy and antiangiogenesis - Drug-specific, dose-related effects. Acta Oncol. 2003;42:294-303.
[33] Jansen M, Hamer PCD, Witmer AN, Troost D, van Noorden CJF. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Rev. 2004;45:143-63.
[34] Miller KD, Sweeney CJ, Sledge GW. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19:1195-206.
[35] O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2:689-92.
[36] Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature reviews Cancer. 2002;2:727-39.
[37] Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-7.
[38] Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nature reviews Cancer. 2003;3:401-10.
[39] Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Res Cancer. 1998;152:341-52.
[40] Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-86.
[41] Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res. 2003;9:1957-71.
[42] Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus J, et al. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol. 2004;60:1220-32.
[43] Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276:1868-71.